Cargando…
Successful Treatment of Sudden Hepatitis Induced by Long-Term Nivolumab Administration
Immune checkpoint inhibitors have drastically changed in the treatment of many kinds of malignancies, especially malignant melanoma. The focus of the recent experiments has not only been on their efficacy but also immune-related adverse events (irAEs). We report a case of fulminant hepatitis due to...
Autores principales: | Imafuku, Keisuke, Yoshino, Koji, Yamaguchi, Kei, Tsuboi, Satoshi, Ohara, Kuniaki, Hata, Hiroo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436031/ https://www.ncbi.nlm.nih.gov/pubmed/28559821 http://dx.doi.org/10.1159/000471480 |
Ejemplares similares
-
Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events
por: Imafuku, Keisuke, et al.
Publicado: (2017) -
Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients
por: Imafuku, Keisuke, et al.
Publicado: (2017) -
Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'
por: Imafuku, Keisuke, et al.
Publicado: (2017) -
Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma
por: Han, Nanumi, et al.
Publicado: (2018) -
Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma
por: Fujimura, Taku, et al.
Publicado: (2018)